Conference Day Two

9:00 am Coffee & Light Breakfast

9:25 am Chair’s Opening Remarks

Translational Modelling for Nasal Drug Delivery to Maximize Practical Drug Applications

9:30 am Quantifying Intranasal Nose to Brain Cell Secretome Delivery to Non-Human Primates and Clinical Translation From Preclinical to Clinical Settings

  • Larry Brown Executive Vice President & Chief Scientific Officer, Noveome Biotherapeutics

Synopsis

  • Quantifying labeled protein techniques to measure drug distribution with biomarker analyses and exploring the therapeutic effect of intranasal delivery in human subjects
  • Discussion of the critical regulatory pathways and methodologies that bridge preclinical findings to clinical applications
  • Clinical case study presentation demonstrating targeted intranasal nose to brain delivery, highlighting key results, challenges faced, and lessons learned

10:00 am Assessing Nasal Drug Delivery in Humans: Bridging Preclinical Insights to Clinical Applications

  • Krishna Subramanian Vice President, Head of Non-clinical &Translational Science, Seelos Therapeutics

Synopsis

  • Examining cutting-edge imaging techniques and biomarker analysis for evaluating drug distribution and nasal delivery efficacy in humans
  • Discussing essential methodologies and pathways that connect preclinical evidence to clinical trial outcomes
  • Reviewing case studies showcasing successful nasal drug delivery, focusing on key findings, challenges, and practical takeaways

10:30 am Roundtable: Innovations and Challenges in Mucoadhesive Systems for Nasal Drug Delivery

Synopsis

  • Discussing advancements in mucoadhesive technologies to enhance nasal drug retention and absorption
  • Identifying challenges related to formulation, adhesion, and patient tolerability
  • Exploring regulatory considerations and testing methods for mucoadhesive-based nasal formulations

11:00 am Break & Networking

11:30 am Strategic Business Decisions & Effective Fundraising for Biotech Companies

Synopsis

  • Strategies to position your biotech for investment success
  • Strategic decision making in fundraising
  • Building and managing relationships and expectations with investors

12:00 pm Transnasal Minimally Invasive Trigeminal Interventions

  • Marc Dean Chairman, Otologic Research Institute
  • Yosef Krespi Professor, Hofstra University Medical School, Lenox Hill Hospital, NYC

Synopsis

  • Trigeminal nerve pathways and their anatomical connections to the brain, highlighting how nasal drug delivery can leverage these routes for targeted delivery
  • Combination of Radiologic and Endoscopic Video assisted Large Language Models (AI) to maximize the efficacy of N2B drug delivery
  • Current research and clinical applications utilizing trigeminal nerve, NALT, Eustachian Tube pathways for drug delivery, emphasizing their potential in enhancing therapeutic outcomes

12:30 pm Lunch Break & Networking

Determining the Efficacy of Delivery Devices to Improve Target Region Delivery

1:30 pm Selecting the Optimal Delivery Device: Options, Challenges and Opportunities (Or a “Shopping List” to Consider)

Synopsis

  • A increasing range of delivery technology is available for purchase or partnering representing a portfolio of options for the drug developer
  • Systematic review of the product development needs, careful definition of key project-specific selection criteria and robust matching with the attributes and limitations of different systems is essential
  • Significant opportunities can be realized through such a judicious approach to the combination of drug and formulation with the optimal delivery device

2:00 pm Navigating Olfera’s Brain Drug Delivery Platform to Examine Optimization of Delivery of Challenging Modalities

  • Parnian Lak Founder & Chief Executive Officer, Olfera

Synopsis

  • OChip, an in vitro screening tool
  • Olfactory prodrugs for brain drug delivery
  • Delivery of challenging modalities

2:30 pm Optimizing Regulatory Guidance for Powder Nasal Delivery Formulation & Devices

  • Laura Andrade Associate Director - Research, Development & Innovation, Insud Pharma

Synopsis

  • Overview of the key regulatory bodies and their guidelines specific to powder nasal delivery systems
  • Best practices for ensuring that both formulation and delivery devices meet regulatory standards, focusing on stability testing, quality control, and consistency in dosing
  • Strategies for streamlining the regulatory approval process, including early engagement with regulatory agencies, comprehensive documentation, and addressing common pitfalls in nasal powder delivery submissions

3:00 pm Chair’s Closing Remarks